Form 8-K - Current report:
SEC Accession No. 0001193125-25-004990
Filing Date
2025-01-13
Accepted
2025-01-13 07:47:24
Documents
16
Period of Report
2025-01-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d910241d8k.htm   iXBRL 8-K 55032
2 EX-2.1 d910241dex21.htm EX-2.1 460190
3 EX-99.1 d910241dex991.htm EX-99.1 62498
7 GRAPHIC g910241img0001.jpg GRAPHIC 3859
  Complete submission text file 0001193125-25-004990.txt   844840

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA itci-20250110.xsd EX-101.SCH 2895
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE itci-20250110_lab.xml EX-101.LAB 17994
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE itci-20250110_pre.xml EX-101.PRE 11291
18 EXTRACTED XBRL INSTANCE DOCUMENT d910241d8k_htm.xml XML 3614
Mailing Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921
Business Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921 (646) 440-9333
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

EIN.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36274 | Film No.: 25524835
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)